Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $74.81, for a total value of $523,670.00. Following the completion of the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at $2,376,788.51. The trade was a 18.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total value of $734,143.86.
• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00.

Oruka Therapeutics Stock Down 3.7%

Shares of ORKA stock traded down $2.81 during mid-day trading on Thursday, hitting $73.87. 1,222,106 shares of the company’s stock were exchanged, compared to its average volume of 1,090,003. The stock has a 50-day simple moving average of $93.48 and a two-hundred day simple moving average of $79.88. Oruka Therapeutics, Inc. has a fifty-two week low of $25.11 and a fifty-two week high of $115.51. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of -36.39 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Algert Global LLC raised its holdings in Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after buying an additional 180 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after buying an additional 250 shares during the last quarter. Nykredit A S acquired a new position in Oruka Therapeutics during the 2nd quarter valued at $29,000. AlphaCentric Advisors LLC lifted its stake in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares during the period. Finally, Orion Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth approximately $91,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ORKA shares. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Guggenheim reiterated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 24th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.91.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.